Home › Breast Cancer › NCT06400563
MRg-NIRS Imaging System Breast Cancer Trial
Recruiting
Evaluation of the Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) Imaging System Platform in Breast Cancer Patients
Who can join
Ages 18 to 83 · Women
Full eligibility criteria
Inclusion Criteria: 1. Females age ≥ 18 years old 2. Participants capable of providing written informed consent 3. Women with a recent diagnosis of breast cancer. 4. Women who are in pre-surgical planning must have an estimated tumor size of 2.0 cm or less on available imaging. 5. Women who are in pre-surgical planning must have had a breast biopsy at least 10 days prior to the MRg-NIRS exam. Exclusion Criteria: 1. Participants with absolute or relative contraindication to MRI: 1. the presence of an electronic implant, such as a pacemaker 2. the presence of a metal implant, such as an aneurysm clip 3. claustrophobia 4. renal failure (FDA's guidance for gadolinium of a creatinine clearance less than 30 mL/1.73 m2 BSA) 2. Pregnant women 3. Breast implants 4. Prisoners 5. Participants with visually inadequate healing from breast biopsy.
About the study
This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast magnetic resonance imaging (MRI).
What is being tested
- MRg-NIRS (device)
Sponsor: Keith D. Paulsen · Participants: 20 · Started: Nov 25, 2024
Contact the study team
- Keith D. Paulsen, PhD · Phone: 603-646-2695
Official record on ClinicalTrials.gov — NCT06400563
Locations in the U.S.
| New Hampshire | Dartmouth-Hitchcock Medical Center, Lebanon |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.